3G, H and Supplementary Fig
for some [dulaglutide (Gerstein et al., 2019), liraglutide (Marso et al., 2016) and semaglutide (Marso et al., 2017)], the CVOTs also confirmed a cardiovascular benefit and eventually led to the approved use of these GLP-1 RAs to reduce cardiovascular risk in people with type 2 diabetes and established CVD or at high cardiovascular risk (Honigberg et al., 2020)
Helps offset fatigue during titration
A 90-day physician-directed Tirzepatide microdosing protocol for patients who want the metabolic benefits of GLP-1 therapy without the side effect profile of full clinical dosing
This slow-and-steady approach is essential for supporting patient comfort and adherence
This can reduce the speed at which glucose enters the bloodstream and can also increase fullness after eating